- Home
- GAIN vs PRTA Comparison
GAIN vs PRTA Comparison
Compare GAIN & PRTA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- GAIN
- PRTA
- Stock Information
- Founded
- GAIN 2005
- PRTA 2012
- Country
- GAIN United States
- PRTA Ireland
- Employees
- GAIN N/A
- PRTA N/A
- Industry
- GAIN Finance: Consumer Services
- PRTA Biotechnology: Pharmaceutical Preparations
- Sector
- GAIN Finance
- PRTA Health Care
- Exchange
- GAIN Nasdaq
- PRTA Nasdaq
- Market Cap
- GAIN 522.8M
- PRTA 472.1M
- IPO Year
- GAIN 2005
- PRTA N/A
- Fundamental
- Price
- GAIN $13.98
- PRTA $9.82
- Analyst Decision
- GAIN Buy
- PRTA Buy
- Analyst Count
- GAIN 2
- PRTA 9
- Target Price
- GAIN $14.00
- PRTA $13.14
- AVG Volume (30 Days)
- GAIN 157.4K
- PRTA 670.3K
- Earning Date
- GAIN 11-04-2025
- PRTA 11-11-2025
- Dividend Yield
- GAIN 15.67%
- PRTA N/A
- EPS Growth
- GAIN 8.96
- PRTA N/A
- EPS
- GAIN 2.16
- PRTA N/A
- Revenue
- GAIN $95,028,000.00
- PRTA $10,341,000.00
- Revenue This Year
- GAIN $6.54
- PRTA N/A
- Revenue Next Year
- GAIN $4.49
- PRTA $602.32
- P/E Ratio
- GAIN $6.49
- PRTA N/A
- Revenue Growth
- GAIN 6.55
- PRTA N/A
- 52 Week Low
- GAIN $11.42
- PRTA $4.32
- 52 Week High
- GAIN $15.34
- PRTA $18.88
- Technical
- Relative Strength Index (RSI)
- GAIN 54.46
- PRTA 53.64
- Support Level
- GAIN $13.71
- PRTA $9.61
- Resistance Level
- GAIN $14.06
- PRTA $10.61
- Average True Range (ATR)
- GAIN 0.30
- PRTA 0.46
- MACD
- GAIN 0.05
- PRTA -0.11
- Stochastic Oscillator
- GAIN 97.23
- PRTA 21.71
About GAIN Gladstone Investment Corporation Business Development Company
Gladstone Investment Corp operates as an externally managed, closed-end, non-diversified management investment company. Its objective is to invest in debt and equity securities of established private businesses operating in the U.S. and to achieve and grow current income by investing in debt securities of established businesses; provide the stockholders with long-term capital appreciation in the value of its assets by investing in equity securities of established businesses. It focuses on investing in lower-middle-market private businesses.
About PRTA Prothena Corporation plc
Prothena Corp PLC is a clinical biotechnology company that focuses on protein dysregulation and a pipeline of investigational therapeutics with the potential to change the course of devastating neurodegenerative and rare and peripheral amyloid diseases. The company's clinical pipeline of antibody-based product candidates targets a range of indications, including Amyloid Light-chain (AL) amyloidosis (NEOD001), Parkinson's disease and other related synucleinopathies (PRX002), and inflammatory diseases, including ATTR amyloidosis [Coramitug (PRX004)], Alzheimer's disease (PRX123), Neurodegeneration (PRXPRX019), and Others.